眼内注射贝伐单抗治疗虹膜转移性乳腺癌
MANAGEMENT OF METASTATIC BREAST CARCINOMA OF IRIS WITH INTRAOCULAR BEVACIZUMAB INJECTIONS.
作者信息
Akinci G Ece, Hondur Ahmet M, Tezel Tongalp H
机构信息
Edward Harkness Institute of Ophthalmology, Columbia University Medical Center, New York, New York.
出版信息
Retin Cases Brief Rep. 2019;13(3):220-223. doi: 10.1097/ICB.0000000000000584.
PURPOSE
To describe intraocular use of bevacizumab for a metastatic breast carcinoma of the iris resistant to advanced systemic chemotherapy protocols, for which conventional treatment would be local radiotherapy or brachytherapy.
METHODS
Case report.
RESULTS
A 65-year-old woman, who was previously diagnosed with breast carcinoma and treated with radical mastectomy coupled with radiotherapy and chemotherapy, presented with an iris mass in her left eye. Four successive intravitreal injections of bevacizumab resulted in progressive regression of the tumor to an almost indiscernible size at 8 months, along with blunting of the highly complex tumor vascular network on fluorescein angiography. At 12 months, the patient's visual acuity remained 20/20, and no ocular or systemic adverse effects were encountered.
CONCLUSION
Intravitreal bevacizumab can offer a simpler and safer solution to treat metastatic iris tumors compared with other treatment options. This report of bevacizumab for treating iris metastasis from breast carcinoma may broaden the treatment options for similar neoplasms of the iris.
目的
描述贝伐单抗眼内注射治疗对晚期全身化疗方案耐药的虹膜转移性乳腺癌，对于该疾病，传统治疗方法为局部放疗或近距离放疗。
方法
病例报告。
结果
一名65岁女性，既往诊断为乳腺癌，接受了根治性乳房切除术并联合放疗和化疗，现左眼出现虹膜肿物。连续4次玻璃体内注射贝伐单抗后，肿瘤在8个月时逐渐缩小至几乎难以辨认的大小，同时荧光素血管造影显示高度复杂的肿瘤血管网络变钝。12个月时，患者视力仍为20/20，未出现眼部或全身不良反应。
结论
与其他治疗选择相比，玻璃体内注射贝伐单抗可为治疗转移性虹膜肿瘤提供更简单、更安全的解决方案。本报告关于贝伐单抗治疗乳腺癌虹膜转移的内容可能会拓宽类似虹膜肿瘤的治疗选择。
Zotero 插件